Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This research study was conducted to compare the safety and effectiveness of the
investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by
the US, European and Asian Health Authorities for the treatment of Hepatitis B infection. The
results for patients taking LdT will be compared to results for patients taking lamivudine.